Advanced search
Publication Cover
OncoImmunology Volume 6, 2017 - Issue 10
Submit an article Journal homepage
1,852
Views
21
CrossRef citations to date
0
Altmetric
Original Research

Characterization of a switchable chimeric antigen receptor platform in a pre-clinical solid tumor model

Elham Pishali BejestaniGerman Cancer Consortium (DKTK), Dresden, Germany;German Cancer Research Center (DKFZ), Heidelberg, Germany
,
Marc CartellieriCellex Patient Treatment GmbH, Dresden, Germany
,
Ralf BergmannHelmholtz-Zentrum Dresden – Rossendorf (HZDR), Dresden, Germany;OncoRay, National Center for Radiation Research in Oncology, University Hospital and Faculty of Medicine Carl Gustav Carus, Helmholtz-Zentrum Dresden – Rossendorf (HZDR), Dresden, GermanyORCID Iconhttp://orcid.org/0000-0002-8733-4286
ORCID Icon,
Armin EhningerGEMoaB Monoclonals GmbH, Dresden, Germany
,
Simon LoffGEMoaB Monoclonals GmbH, Dresden, Germany
,
Michael KramerMedical Department I, University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany
,
Johannes SpehrCellex Patient Treatment GmbH, Dresden, Germany
,
Antje DietrichGerman Cancer Consortium (DKTK), Dresden, Germany;German Cancer Research Center (DKFZ), Heidelberg, Germany;OncoRay, National Center for Radiation Research in Oncology, University Hospital and Faculty of Medicine Carl Gustav Carus, Helmholtz-Zentrum Dresden – Rossendorf (HZDR), Dresden, Germany
,
Anja FeldmannHelmholtz-Zentrum Dresden – Rossendorf (HZDR), Dresden, Germany
,
Susann AlbertUniversityCancerCenter (UCC), University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany
,
Martin WermkeMedical Department I, University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany;UniversityCancerCenter (UCC), University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany
,
Michael BaumannGerman Cancer Consortium (DKTK), Dresden, Germany;German Cancer Research Center (DKFZ), Heidelberg, Germany;Helmholtz-Zentrum Dresden – Rossendorf (HZDR), Dresden, Germany;Department of Radiation Oncology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany;OncoRay, National Center for Radiation Research in Oncology, University Hospital and Faculty of Medicine Carl Gustav Carus, Helmholtz-Zentrum Dresden – Rossendorf (HZDR), Dresden, Germany;National Center for Tumor Diseases (NCT), Dresden, Germany
,
Mechthild KrauseGerman Cancer Consortium (DKTK), Dresden, Germany;German Cancer Research Center (DKFZ), Heidelberg, Germany;Helmholtz-Zentrum Dresden – Rossendorf (HZDR), Dresden, Germany;Department of Radiation Oncology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany;OncoRay, National Center for Radiation Research in Oncology, University Hospital and Faculty of Medicine Carl Gustav Carus, Helmholtz-Zentrum Dresden – Rossendorf (HZDR), Dresden, Germany;National Center for Tumor Diseases (NCT), Dresden, Germany
,
Martin BornhäuserGerman Cancer Consortium (DKTK), Dresden, Germany;Medical Department I, University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany;UniversityCancerCenter (UCC), University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany;National Center for Tumor Diseases (NCT), Dresden, Germany
,
Gerhard EhningerGerman Cancer Consortium (DKTK), Dresden, Germany;German Cancer Research Center (DKFZ), Heidelberg, Germany;Cellex Patient Treatment GmbH, Dresden, Germany;GEMoaB Monoclonals GmbH, Dresden, Germany;Medical Department I, University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany;UniversityCancerCenter (UCC), University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany;National Center for Tumor Diseases (NCT), Dresden, Germany
,
Michael BachmannGerman Cancer Consortium (DKTK), Dresden, Germany;German Cancer Research Center (DKFZ), Heidelberg, Germany;Cellex Patient Treatment GmbH, Dresden, Germany;Helmholtz-Zentrum Dresden – Rossendorf (HZDR), Dresden, Germany;GEMoaB Monoclonals GmbH, Dresden, Germany;UniversityCancerCenter (UCC), University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany;National Center for Tumor Diseases (NCT), Dresden, GermanyORCID Iconhttp://orcid.org/0000-0002-8029-5755
ORCID Icon &
Malte von BoninGerman Cancer Consortium (DKTK), Dresden, Germany;German Cancer Research Center (DKFZ), Heidelberg, Germany;Medical Department I, University Hospital Carl Gustav Carus, Technische Universität Dresden, GermanyCorrespondence[email protected]
 show all
Article: e1342909 | Received 02 Dec 2016, Accepted 09 Jun 2017, Published online: 21 Jul 2017

Citations (21)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Varada Date & Sujit Nair. (2021) Emerging vistas in CAR T-cell therapy: challenges and opportunities in solid tumors. Expert Opinion on Biological Therapy 21:2, pages 145-160.
Read now
Jan-Erik Meyer, Simon Loff, Josephine Dietrich, Johannes Spehr, Gabriel Jurado Jiménez, Malte von Bonin, Gerhard Ehninger, Marc Cartellieri & Armin Ehninger. (2021) Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML. OncoImmunology 10:1.
Read now

Articles from other publishers (19)

Laura Hidalgo, Beatriz Somovilla-Crespo, Patricia Garcia-Rodriguez, Alvaro Morales-Molina, Miguel Angel Rodriguez-Milla & Javier Garcia-Castro. (2023) Switchable CAR T cell strategy against osteosarcoma. Cancer Immunology, Immunotherapy 72:8, pages 2623-2633.
Crossref
Fanyi Meng, Siqi Zhang, Juan Xie, Yuan Zhou, Qingling Wu, Binyan Lu, Shixin Zhou, Xiangyu Zhao & Yang Li. (2023) Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells. Journal of Hematology & Oncology 16:1.
Crossref
Piotr Celichowski, Marcello Turi, Sandra Charvátová, Dhwani Radhakrishnan, Neda Feizi, Zuzana Chyra, Michal Šimíček, Tomáš Jelínek, Juli Rodriguez Bago, Roman Hájek & Matouš Hrdinka. (2023) Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility. Journal of Translational Medicine 21:1.
Crossref
Claudia Arndt, Antje Tunger, Rebekka Wehner, Rebecca Rothe, Eleni Kourtellari, Stephanie Luttosch, Katharina Hannemann, Stefanie Koristka, Liliana R. Loureiro, Anja Feldmann, Torsten Tonn, Theresa Link, Jan Dominik Kuhlmann, Pauline Wimberger, Michael Philipp Bachmann & Marc Schmitz. (2023) Palbociclib impairs the proliferative capacity of activated T cells while retaining their cytotoxic efficacy. Frontiers in Pharmacology 14.
Crossref
Sophia Stock, Mohamed-Reda Benmebarek, Anna-Kristina Kluever, Diana Darowski, Christian Jost, Kay-Gunnar Stubenrauch, Joerg Benz, Anne Freimoser-Grundschober, Ekkehard Moessner, Pablo Umana, Marion Subklewe, Stefan Endres, Christian Klein & Sebastian Kobold. (2022) Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors. Journal for ImmunoTherapy of Cancer 10:7, pages e005054.
Crossref
Le Wang. (2022) Clinical determinants of relapse following CAR-T therapy for hematologic malignancies: Coupling active strategies to overcome therapeutic limitations. Current Research in Translational Medicine 70:1, pages 103320.
Crossref
Heleen Hanssens, Fien Meeus, Kim De Veirman, Karine Breckpot & Nick Devoogdt. (2021) The antigen‐binding moiety in the driver's seat of CARs. Medicinal Research Reviews 42:1, pages 306-342.
Crossref
Stefan Lundh, Sayantan Maji & J. Joseph Melenhorst. (2020) Next-generation CAR T cells to overcome current drawbacks. International Journal of Hematology 114:5, pages 532-543.
Crossref
Martin WermkeSabrina KrausArmin EhningerRalf C. Bargou, Maria-Elisabeth Goebeler, Jan Moritz MiddekeCarla Kreissig, Malte von BoninJan KoedamMichael PehlMartin BornhäuserHermann EinseleGerhard EhningerMarc Cartellieri. (2021) Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML. Blood 137:22, pages 3145-3148.
Crossref
Simon Loff, Josephine Dietrich, Jan-Erik Meyer, Julia Riewaldt, Johannes Spehr, Malte von Bonin, Cordula Gründer, Mridula Swayampakula, Kristin Franke, Anja Feldmann, Michael Bachmann, Gerhard Ehninger, Armin Ehninger & Marc Cartellieri. (2020) Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia. Molecular Therapy - Oncolytics 17, pages 408-420.
Crossref
Evan W. Weber, Marcela V. Maus & Crystal L. Mackall. (2020) The Emerging Landscape of Immune Cell Therapies. Cell 181:1, pages 46-62.
Crossref
Dong Kim & Je-Yoel Cho. (2020) Recent Advances in Allogeneic CAR-T Cells. Biomolecules 10:2, pages 263.
Crossref
Yuan Mao, Weifei Fan, Hao Hu, Louqian Zhang, Jerod Michel, Yaqin Wu, Jun Wang, Lizhou Jia, Xiaojun Tang, Li Xu, Yan Chen, Jin Zhu, Zhenqing Feng, Lin Xu, Rong Yin & Qi Tang. (2019) MAGE-A1 in lung adenocarcinoma as a promising target of chimeric antigen receptor T cells. Journal of Hematology & Oncology 12:1.
Crossref
Delong Liu, Juanjuan Zhao & Yongping Song. (2019) Engineering switchable and programmable universal CARs for CAR T therapy. Journal of Hematology & Oncology 12:1.
Crossref
Ya.Yu. Kiseleva, A.M. Shishkin, A.V. Ivanov, T.M. Kulinich & V.K. Bozhenko. (2019) CAR T-cell therapy of solid tumors: promising approaches to modulating antitumor activity of CAR T cells. Bulletin of Russian State Medical University:5, pages 5-12.
Crossref
Shahin Hallaj, Fatemeh Meshkini, Mitra Ghasemi Chaleshtari, Anahita Ghorbani, Afshin Namdar, Hassan Soleimanpour & Farhad Jadidi-niaragh. (2019) Conjugated CAR T cell one step beyond conventional CAR T cell for a promising cancer immunotherapy. Cellular Immunology 345, pages 103963.
Crossref
Susann Albert, Stefanie Koristka, Alexander Gerbaulet, Marc Cartellieri, Claudia Arndt, Anja Feldmann, Nicole Berndt, Liliana R. Loureiro, Malte von Bonin, Gerhard Ehninger, Anne Eugster, Ezio Bonifacio, Martin Bornhäuser, Michael P. Bachmann & Armin Ehninger. (2019) Tonic Signaling and Its Effects on Lymphopoiesis of CAR-Armed Hematopoietic Stem and Progenitor Cells. The Journal of Immunology 202:6, pages 1735-1746.
Crossref
Dongdong Ti, Yunfei Niu, Zhiqiang Wu, Xiaobing Fu & Weidong Han. (2018) Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy. Science China Life Sciences 61:11, pages 1320-1332.
Crossref
Susann Albert, Claudia Arndt, Stefanie Koristka, Nicole Berndt, Ralf Bergmann, Anja Feldmann, Marc Schmitz, Jens Pietzsch, Jörg Steinbach & Michael Bachmann. (2018) From mono- to bivalent: improving theranostic properties of target modules for redirection of UniCAR T cells against EGFR-expressing tumor cells in vitro and in vivo . Oncotarget 9:39, pages 25597-25616.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.